Alnylam Pharmaceuticals this week released new preclinical data from programs in beta-thalassemia and erythropoiesis — indications from which the company could select its newest pipeline candidate.

Alnylam, which presented the data at the American Society of Hematology annual meeting, said that it and collaborators showed that the systemic administration of a lipid nanoparticle-formulated siRNA targeting the gene transmembrane protease, serine 6, triggered an increase in hepcidin mRNA levels in mouse models of iron overload in beta-thalassemia.